Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru-Reference-Cited by-同舟云学术

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

Published:2002-06 Issue:9322 Volume:359 Page:1980-1989
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Suárez Pedro G,Floyd Katherine,Portocarrero Jaime,Alarcón Edith,Rapiti Elisabetta,Ramos Gilbert,Bonilla Cesar,Sabogal Ivan,Aranda Isabel,Dye Christopher,Raviglione Mario,Espinal Marcos A

Publisher

Elsevier BV

Subject

General Medicine

Reference38 articles.

1. Global surveillance for antituberculosis-drug resistance, 1994–1997;Pablos-Méndez;N EnglJ Med,1998

2. Global trends in resistance to antituberculosis drugs;Espinal;N Engl J Med,2001

3. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries;Espinal;JAMA,2000

4. Guidelines for the management of drug-resistant tuberculosis,1997

5. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin;Goble;N Engl J Med,1993

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses;PharmacoEconomics;2024-08-07

2. Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-01-25

3. Costs of services and funding gap of the Bangladesh National Tuberculosis Control Programme 2016–2022: An ingredient based approach;PLOS ONE;2023-06-02

4. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis;Journal of International Medical Research;2023-01

5. Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings;JAC-Antimicrobial Resistance;2022-03-18